A
AAVantgarde Bio
Clinical stage biotechnology company validating proprietary AAV platforms in the clinic in two inherited retinal diseases
About AAVantgarde Bio
AAVantgarde Bio is an international biotechnology company, based in Italy, that operates in the clinical stage. The company's primary focus is on gene therapy, specifically utilizing Adeno-Associated Viral (AAV) vectors. These vectors have been instrumental in treating genetic illnesses, but their application has been limited due to their small vector payload. AAVantgarde Bio is working to overcome this limitation by developing technology platforms that can handle oversized gene delivery. This could potentially open up opportunities for delivering genetic medicine to more patients suffering from debilitating diseases.
The company's business model revolves around the development and validation of its two proprietary AAV platforms. These platforms are currently being tested in the clinic for two inherited retinal diseases. If successful, the technology could be extended to treat a variety of other disease areas.
AAVantgarde Bio's primary clients are patients with genetic illnesses that are currently underserved by existing treatments. The company generates revenue through the development and commercialization of its gene therapy technologies. As the company's technologies are still in the clinical trial stage, it is likely that a significant portion of its revenue comes from investors and research grants.
In summary, AAVantgarde Bio is a pioneering biotech company that is pushing the boundaries of gene therapy. Its innovative approach to overcoming the limitations of AAV vectors could potentially revolutionize the treatment of genetic diseases.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Milan, Italy
- Employees
- 70
- Open positions
- None listed
- Dealroom signal
- 86.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2025 | $141M | $564M | CDP Venture Capital · Athos Capital · XGEN Venture · Forbion Capital Partners | ↗ |
| SERIES AOther financing | Jun 2023 | $67M | $268M | Sofinnova Partners · Atlas Venture · Forbion Capital Partners · Longwood Fund | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for AAVantgarde Bio is 1.1K monthly website visits, up 144.4% over the last three months. AAVantgarde Bio's team grew 14.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A11 investors entered at this stage
Atlas Venture
Forbion Capital Partners
Longwood Fund
Schroders Capital
CDP Venture Capital
Athos Capital
XGEN Venture
Willett Advisors
Sixty Degree Capital
Amgenbd
NEVA SGR
Other known investors3 additional known investors
Tigem
Fondazione Telethon
University of Naples Federico II
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AAVantgarde Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AAVantgarde Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.